Decoy Therapeutics Inc. (DCOY) Earnings Call Transcripts

Decoy Therapeutics Inc.'s Latest Earnings Call - April 9, 2026

In the Q1 2026 earnings call, Decoy Therapeutics (DCOY:US) outlined significant advancements in its pipeline, particularly the transition of its Designable Multi-Antivirals (D-MAVs) into clinical stages. The company is targeting a $4.9 billion to $6 billion market with its pan-coronavirus program, backed by notable funding from the Gates Foundation and other entities. Management maintained its timeline for clinical trials, with expectations to initiate two IND filings within the next two years, signaling strong growth potential. Revenue and earnings figures were not disclosed, but the company emphasized its innovative approach and market positioning, which could drive stock performance in the near future.

Reported metrics

Guidance from management

Management maintained its goal of initiating two IND filings within the next two years, emphasizing a commitment to rapid clinical development and market entry.

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape and the execution risks associated with transitioning from preclinical to clinical stages. There were questions about the scalability of production and the timeline for achieving human proof of concept.

Main topics on the call

• Pipeline Advancement — Decoy Therapeutics is advancing its D-MAV programs into clinical stages, with plans to enter the clinic for its pan-coronavirus product in the first half of 2027 and the DCOY-TRI program by 2028. CEO Frederick Pierce sta...
• Market Opportunity — The company is targeting a significant market opportunity, with the pan-coronavirus program positioned in a $4.9 billion to $6 billion market. Management highlighted the urgent need for better antivirals, stating, "there...
• Funding and Partnerships — Decoy has secured funding from prominent organizations, including the Gates Foundation, Google, and BARDA, which supports its development initiatives. The CEO noted, "We've received $6.5 million, $5 million from the Gate...
• Technological Innovation — The company is leveraging AI and machine learning to accelerate drug design and testing processes, which has improved workflow efficiency by 25 to 100 times. Pierce mentioned, "Today, there's a dashboard... they can do i...

Read the full Decoy Therapeutics Inc. transcript (April 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 13 Decoy Therapeutics Inc. earnings call transcripts on record, spanning February 17, 2020 to April 9, 2026. Based on this history, Decoy Therapeutics Inc. reports semi-annually. The most recent call on file is dated April 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DCOY

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

13

First call

February 17, 2020

Most recent

April 9, 2026

Reporting cadence

semi-annually